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Nonsyndromic X-linked mental retardation (MRX) is defined by an X-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms of MR for which
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in both MRXS and MRX, including MECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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Figure 1 A, Ideograms depicting normal chromosomes X and 7 and their derivatives der(X) and der(7). Patient metaphase chromosomes
were used for FISH of X-chromosomal breakpoint-spanning cosmid clone LAII14H20 with signals on the normal X and split signals on der(X)
and der(7) as indicated (B), and chromosome 7 breakpoint-spanning BAC clone RP11-196D18 (GenBank accession number AC069285) with
signals on the normal 7 and split signals on der(7) and der(X) as indicated (C).
2002), FGD1 (MIM 305400) (Pasteris et al. 1994; Lebel
et al. 2002), RSK2 (MIM 300075) (Trivier et al. 1996;
Hanauer and Young 2002), ATRX (MIM 300032) (Gib-
bons et al. 1995; Villard et al. 1996b), and L1CAM (MIM
308840) (Jouet et al. 1994; Brewer et al. 1996). Studies
of L1CAM mutations in a family with a variety of neu-
rologic abnormalities (Fryns et al. 1991; Ruiz et al. 1995)
highlighted the fact that a specific mutation can result in
widely variable phenotypes even within a family.
Given the low mutation frequency in currently known
MRX genes, together with the number of families for
which linkage data implicate unidentified X-chromoso-
mal genes, it can be assumed that there are as many as
30–100 MRX genes that remain to be discovered (Ropers
et al. 2003). In the search for candidate MRX genes,
molecular characterization of de novo chromosome ab-
normalities has proved to be a promising starting point.
Given the large percentage of noncoding DNA in the
human genome, it is not surprising that balanced trans-
locations, which occur at a frequency of ∼1 in 2,000 live
births (Warburton 1991), are often present in healthy
individuals. However, among carriers of balanced trans-
locations, the frequency of congenital abnormalities is
double that among individuals with normal karyotypes
(Warburton 1991), suggesting that, in approximately half
of disease-associated balanced translocations, there is a
causal relationship between the translocation and the dis-
order. Since many balanced translocations do not disrupt
genes, it is reasonable to expect that, among those that
do disrupt genes or control elements, a causal relationship
is much more frequent. X-chromosomal genes that are
disrupted by balanced translocations in individuals with
developmental anomalies are especially good candidate-
disease genes because X-chromosomal genes typically
have only one functional copy. This applies in the case
of females as it does in the case of males because female
balanced-translocation carriers exhibit skewed X inac-
tivation, was 118limiting transcription of X-chromo-
somal genes to those on the translocated chromosome
(Schmidt and DuSart 1992).
In the current study, we investigated the chromosome
breakpoints in a female patient with severe MRX who
carries a de novo balanced X;7 translocation. Cloning of
the breakpoint-spanning DNA fragment, gene expression
studies, and mutation screening in unrelated families
have enabled us to identify a novel candidate gene for
nonsyndromic XLMR.
Subjects and Methods
Patient with Translocation
The proband is a 7-year-old girl who presents with
severe developmental delay and carries a de novo bal-
anced chromosome rearrangement t(X;7)(p11.3;q11.21)
(depicted in fig. 1A). She is the daughter of healthy un-
related parents, and there is no family history of mental
disability or related illness. She has two healthy siblings.
After normal pregnancy and birth, she had an Apgar
score of 10/10, birth weight was 3,130 g (25th percen-
tile, on the basis of the National Center for Disease Con-
trol and Prevention), length was 51 cm (50th percentile),
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and head circumference was 33.5 cm (25th percentile).
At age 1 wk, she had metatarsus adductus. At age 3 mo,
an umbilical hernia was observed.
At age 2 years, the patient did not yet walk or speak,
and she exhibited clearly delayed psychomotor develop-
ment. At age 3 years 9 mo, occasional convulsions, pre-
dominantly localized to the shoulders and upper back,
were reported, which led to the diagnosis of myoclonic
epilepsy. At age 5 years 6 mo, her physical development
was in the normal range. She had no dysmorphic fea-
tures, and her skin was normal; that is, there was no
evidence of genetic mosaicism. She could speak, but she
was unable to create sentences of more than four words.
On clinical examination at age 6 years 4 mo, her height
was 118 cm (50th percentile), her weight was 25 kg
(90th percentile), and she was friendly and cooperative.
She had some difficulty standing on one leg and walking
along a line, which suggested minor ataxia. Routine lab-
oratory tests, including thyroid hormone and ammo-
nium levels, had normal results. Screening for inborn
errors of metabolism resulted in no indication of amino
acidopathies or organic acidurias. MRI results were nor-
mal; the electroencephalogram (EEG) exhibited a spike-
wave pattern. The patient continued to suffer from myo-
clonic seizures and was treated with valproate and etho-
suximide. EEG was normal 1 year later. Samples from
patient and parents were obtained after receiving in-
formed consent.
Families with XLMR and Control Individuals
DNA from 200 families collected by the European
XLMR Consortium, including 14 families for which
linkage data implicates the Xp11 region, was available
for mutation screening. DNA from an additional 10
Australian families with MRX linked to the Xp11 region
was also included in the panel for screening. The control
panel consisted of 275 normal males and 65 normal fe-
males. All samples were obtained after receiving informed
consent.
FISH
Chromosome analysis was performed using standard
high-resolution techniques. For breakpoint mapping, we
used CEPH and ICRFy900 YAC probes—selected from
the Whitehead Institute and the Integrated X Chromo-
some Database contigs—and BACs and PACs from the
Sanger Institute and the University of California–Santa
Cruz (UCSC) “Golden Path.” Cosmid clones were se-
lected from the chromosome X–specific cosmid library
(LANL), available from the RZPD Deutsches Ressour-
cenzentrum fu¨r Genomforschung (RZPD). Clones were
prepared by standard techniques, were labeled with ap-
propriately coupled dUTPs by nick translation or were
directly labeled by degenerate oligonucleotide primer–
PCR, and were used as probes in FISH, as described
elsewhere (Wirth et al. 1999).
Southern Blotting and Breakpoint Cloning
DNA isolation and Southern blotting were performed
according to standard protocols. Following overnight re-
striction endonuclease digestion, genomic DNA was sep-
arated by agarose gel electrophoresis, was transferred in
to Nylon membranes (Roth), and was cross-20# SSC
linked by UV. Probes of PCR-amplified genomic DNA
were labeled with 32[P]dCTP, by Klenow reaction with
random hexamer primers. After preannealing to sonicated
human placental DNA (HT Biotechnology), probes were
hybridized to membranes in polyethylene glycol hybrid-
ization buffer (10% PEG 6000; 0.125 M NaPO4; 0.25
M NaCl; 0.001 M EDTA; 7% SDS) supplemented with
salmon sperm DNA. Blots were washed in 0.2#
SDS before exposure to radiographic film.SSC/0.2%
Primer pairs for amplification of probes were based on
the genomic sequence of clone RP13-83I24 (GenBank
accession number AL590283) and are as follows: 13
forward 5′-GTG TGT TGA AAT GTG ATT TCT GG-3′
and 1,055 reverse 5′-AAT TCC TGG AGG AAT TTT
CTT CC-3′, 5,705 forward 5′-AAA AGA CTG AAC
AGG AGA AAA GG-3′ and 6,553 reverse 5′-TCT CCA
TAT CCA TTC TTT ATG CC-3′, 9,087 forward 5′-ATG
CAC TAC AGA GTT TAT GTG AG-3′ and 10,112 re-
verse 5′-TTC TCT TGG GCT TTA CTC TAT TG-3′,
15,123 forward 5′-AAC TCG CTT CAG TTA TAC CAT
TC-3′ and 16,128 reverse 5′-TTT TCA TTA AAC ATC
AGG GAG CG-3′, 26,828 forward 5′-GAG TGA AAA
AAG AAG CTA TTG CC-3′ and 27,466 reverse 5′-GGT
CAA AGG CAA TTT TCC TTA TG-3′. Breakpoint clon-
ing was performed essentially as described elsewhere
(Siebert et al. 1995). Patient genomic DNA was subject
to restriction digest with EcoRI, was ligated to adaptors,
and was amplified with adaptor-specific primers (AP1
and AP2) and nested X chromosome sequence-specific
primers 5′-CAC ACA GAT AGA GAC GAT ACA-3′
(primer 1) and 5′-TCT TAC AGA CCA TCT CTA AAC
C-3′ (primer 2). Following nested PCR, DNA of the ex-
pected size was gel purified with the QIAquick gel ex-
traction kit (Qiagen) and was cloned into pGEMTeasy
(Promega), and the inserted breakpoint fragment was
sequenced with the BigDye Terminator Chemistry (PE
Biosystems) and was separated on an ABI 377 DNA
sequencer.
RNA Isolation and Expression Studies
RNA was isolated from lymphoblastoid cells by use of
Trizol (Invitrogen), according to the manufacturer’s rec-
ommendations. For reverse transcription (RT) with Su-
perscript II (Invitrogen), 5 mg of RNA was used. RT re-
actions were performed essentially according to the manu-
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Table 1
Primers for Mutation Detection and PCR Amplification Conditions
Exon Forward Primer (5′r3′) Reverse Primer (5′r3′) Annealing Temperature MgCl2 Concentration
2 GTTGTCAGCAGGAGAGCCTG TGTCTCCAGGGTGGCAGGTC 64C 3 mM
3 GCATTAAAAACAACTTGCTATC ATGGAAATACCCTCATTAGCAG 56C 2 mM
4 CCAATCAGCTGGACCCAATC GTGATACTGACTTCCATGTCC 62C 4 mM
5a CTGCTGATTGTTCTTTGTGTCG ATTGTGTCACAGTTATGGAGTC 61C 4 mM
5b ATAATTCATGTGACTACCAAGC CCATTACACATTCAGTACACAC 61C 4 mM
5c CCACCCACCATCAGAAAATTC TCAGATGTCTAAAGAGGTCTG 59C 3 mM
5d AGAAACCCTACAAATGCAGTG CTCCAGTATGAATTCTCTGATG 59C 2.25 mM
5e GGCCTTCATCCAGAAATCAC CCACAGCCATTGCACTTATAG 61C 4 mM
5f AAAGGCTTTTACTGACCAGTC TGCATTCATAAGGCTTCTCTC 59C 4 mM
5g AGAAATCGCACTTCATTGCGC TCTGGATGAAAGCTTTCCCAC 61C 4 mM
5h AGTCTCATACTGGAGAAAGAC CTGCTATTAGATACCTGATGC 59C 3 mM
facturer’s protocol but in the presence of RNAguard
(Amersham Pharmacia), by use of either oligo dT or ran-
dom hexamers for priming. Amplification of hypoxan-
thine phosphoribosyltransferase (HPRT) with intron-
spanning primers (TGG CGT CGT GAT TAG TGA TG
and TAT CCA ACA CTT CGT GGG GT) served as a
cDNA loading control. Breakpoint-spanning primers
(ATG GCA GCT AAT GGG GAC TC and CCT GAA
CAG CTC TGA TGT GG) or primers 3′ to the breakpoint
(AGT CAG AGG CTG CCT TCA AG and AGT AGA
GGA AGG GCT ATG GG) were used to amplify trans-
location patient and control ZNF41 transcripts. Splice
variants in patients and control individuals were amplified
with one of the two forward primers—F1 (CTT CGG
AGC TGA CAC TAA GC) or F2 (ATG GCA GCT AAT
GGG GAC TC)—and the reverse primer, CTG TTC AAG
GCA GCA TGG TC, that is specific for known ZNF41
variants 41.3 and 41.6. Human multiple-tissue northern
blots (Clontech) were probed with a gel-purified 3′ ZNF41
fragment that had been amplified by RT-PCR as described
above and had been labeled as for Southern blotting. Blots
were hybridized in QuikHyb (Stratagene), according to
manufacturer’s protocol. To control for RNA loading,
blots were hybridized either to the b-actin probe provided
or to a G3PDH fragment amplified with the following
primers: ACC CCT TCA TTG ACC TCA ACT AC and
TGC TTC ACC ACC TTC TTG ATG TC.
Mutation Screening by Denaturing High-Performance
Liquid Chromatography (DHPLC)
PCR products with a range of 100–300 nt in length
and corresponding to the complete known human ZNF41
coding sequence plus 40 nt of neighboring intronic
sequences were amplified from genomic DNA and were
analyzed by DHPLC. The screened coding sequence cor-
responds to ZNF41 mRNA transcript variant 1 (also
referred to as “ZNF41.1” [GenBank accession number
NM_007130]) and to the 3′ exon 2 extension indicated
by the sequence ZNF41.6 (GenBank accession number
AJ010021) and the 5′ exon 3 extension indicated by the
sequences ZNF41.6 and ZNF41.3 (GenBank accession
number AJ010018). Exon 5 was amplified in eight over-
lapping fragments (exons 5a–5h). PCR reactions were
carried out in 50-ml reaction volumes containing 100 ng
of genomic DNA, 300 pmol of each primer, 0.4 mM
dNTPs, 1 U Amplitaq DNA polymerase (Perkin Elmer),
and 2–4 mM MgCl2, with the exception of exon 5d,
which was amplified using 1.5 U Taq DNA polymerase
and Q-Solution (Qiagen). An initial 5-min denaturation
at 95C was followed by 35 cycles of 1 min at 95C, 1
min of annealing, a 1.5-min extension at 72C, and a
final extension step of 10 min at 72C. Sequences of
primer pairs and specific amplification conditions are
indicated in table 1. Products were checked by 1.5%
agarose gel electrophoresis before analysis by WAVE nu-
cleic acid fragment analysis system (Transgenomic).
Paired products were denatured at 95C for 5 min and
were slowly brought to room temperature. Reannealed
DNA duplexes were injected and eluted with a linear
acetonitrile gradient at a flow rate of 0.9 ml/min, with
a mobile phase consisting of a mixture of buffer A (0.1
M triethylammonium acetate or TEAA with 0.1%
acetonitrile) and buffer B (0.1 M TEAA with 25%
acetonitrile).
Melting profiles and resolution temperatures for each
fragment were predicted by the Transgenomic WAVE-
MAKER software, version 4.1. For each pair of patient
or control samples exhibiting exceptional elution pro-
files, DNA was reamplified and gel purified using the
QIAquick gel extraction kit (Qiagen), was sequenced us-
ing the BigDye Terminator Chemistry (PE Biosystems),
and was separated on an ABI 377 DNA sequencer.
Results
X Chromosome Breakpoint Mapping by FISH
The translocation patient in this study had been
screened for abnormalities in the FMR1 and FMR2 (MIM
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Table 2
FISH Results for CEPH or ICRF YAC Clones
Mapping to Chromosome X
YAC Clonea Location on Xb FISH Result
iA1034 42 cM Distal
749G05 68 cM Distal
iF02014 NA Distal
iB01003 NA Distal
iC04013 NA Distal
896E11 73 cM Distal
iB01128 NA Distal
iB07021 NA Distal
iB01026 77 cM Distal
iB02007 77 cM Distal
iD01151 77 cM Distal
964C07 77 cM Distal
iC1228 77 cM Overlapping
iA0120 NA Proximal
iA1220 77 cM Proximal
iC1022 77 cM Proximal
iC0874 NA Proximal
a i p ICRF.
b NA p not available.
Table 3
FISH Results for BAC, PAC, and Cosmid Clones
Clone
GenBank
Accession
Numbera FISH Result
RP11-30G10 AQ003212 Distal
RP4-733D15 AL023623 Distal
RP11-75A9 AL139811 Distal
RP1-71L16 AL022165 Distal
RP1-250J21 AL162583 Distal
RP3-484G21 AL163597 (STS) Distal
RP11-553I6 AL359698 Distal
RP1-306D1 Z83822 Distal
RP1-659F15 AL096791 Distal
RP11-571E6 AL591503 Distal
RP11-479F17 AL590223 Distal
LAII14H20 NA Overlapping
LAII33P05 NA Proximal
LAII59H11 NA Proximal
LAII61J11 NA Proximal
RP11-83I24 AL590283 Proximal
RP1-1147B6 NA Proximal
RP1-230G1 AQ489515 Proximal
RP1-212G6 AL009172 Proximal
RP3-473A14 AL031967 Proximal
RP3-393P12 AL022578 Proximal
a NA p not available.
309548) genes; disease-causing triplet repeats were ruled
out. The de novo translocation t(X;7)(p11.3;q11.21), de-
picted in fig. 1A, indicates a disruption in a region of the
X chromosome to which several families with MRX have
been mapped (Chelly and Mandel 2001; Ropers et al.
2003). Successive FISHs of genomic YAC clones to patient
metaphase chromosomes localized the breakpoint to a
region of !1 cM (table 2). Clone ICRFy900C1228, har-
boring marker DXS426, was breakpoint spanning (data
not shown). Hybridization of BAC and PAC clones within
the region of the overlapping YAC (table 3) led to the
identification of two clones, RP13-83I24 (GenBank ac-
cession number AL590283) and RP13-479F17 (GenBank
accession number AL590223)—with partially overlap-
ping sequence—that gave proximal and distal hybridi-
zation signals, respectively (data not shown), suggesting
that the breakpoint might lie in the region of sequence
overlap. PCR products from within this region (nts 1–
20585 of clone RP13-83I24) were used for screening of
a human chromosome X-specific cosmid library. Positive
clones were FISH mapped (table 3), and cosmid clone
LAII14H20 gave split signals (fig. 1B), indicating that it
spans the breakpoint.
Localization of the X chromosome Breakpoint
by Southern Hybridization and Subsequent Breakpoint
Cloning
Further breakpoint localization within the region of the
overlapping cosmid was done by Southern blot hybridi-
zations. Aberrant restriction fragments in patient DNA
were observed in several independent digests, by use of
a probe corresponding to nts 9529–10112 of clone
RP13-83I24 (fig. 2A). In particular, the aberrant frag-
ment of ∼1 kb in the patient EcoRI digest enabled us
to locate precisely the breakpoint. Subsequent cloning
and sequencing of this hybrid fragment (fig. 2B) indi-
cated that the chromosome 7 breakpoint lies within BAC
clone RP11-196D18 (GenBank accession number
AC069285). This result was confirmed by FISH (fig.
1C).
The Rearrangement Disrupts the X-Chromosomal
ZNF41 Gene, and Full-Length Transcripts Are Absent
in the Patient Cell Line
In both breakpoint regions identified in this patient,
fully annotated genome sequences are available; therefore,
a thorough in silico search for genes and other potential
links between genotype and phenotype was possible. Both
chromosomes are disrupted within LINE1 repetitive ele-
ments (L1ME on X and L1 on 7). On chromosome X,
the breakpoint clearly interrupts the coding sequence of
the zinc-finger 41 gene (ZNF41 [MIM 314995]). The
breakpoint lies within intron 2 (notation is based on the
presence of five exons, one of which is composed strictly
of 5′ UTR), thereby truncating the predicted ZNF41 pro-
tein (GenBank accession number NP_009061) just after
amino acid 24 (fig. 3A). Analysis of patient metaphase
chromosomes confirmed skewed X inactivation (data not
shown). Correspondingly, full-length ZNF41 transcripts
were not present in the patient cell line, whereas tran-
scripts were easily detected in control cell lines (fig. 3B).
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Figure 2 A, Southern blot of patient (P) and control (C) genomic DNA probed with a PCR product corresponding to nucleotides 9529–
10112 of clone RP11-83I24. Aberrant fragments specific to patient DNA (black arrows) in HincII (left) and EcoRI (right) digests correspond
to sizes of ∼10 kb and ∼1 kb, respectively. B, Sequence of the breakpoint region indicating (in large type) the three nucleotides common to
both chromosome X and chromosome 7.
Figure 3 A, Schematic diagram (not to scale) indicating the
exon-intron structure of ZNF41 relative to the breakpoint location.
Arrows indicate location of primers used for RT-PCR analysis. B, RT-
PCR analysis by use of ZNF41 primers spanning the breakpoint.ZNF41
product corresponds to nucleotides 407–702 of GenBank accession
number NM_007130. Amplification of HPRT served as a control. A
plus sign () indicates with reverse transcriptase; a minus sign ()
indicates mock reaction.
HPRT, however, was present at normal levels in the pa-
tient. Data shown are representative examples from sev-
eral independent experiments.
The chromosome 7 breakpoint does not disrupt any
known genes, and, on the basis of both UCSC “Golden
Path” (April 2003 freeze) and NIX (UK Human Genome
Mapping Project Resource Centre) analyses, there are no
ESTs bridging the breakpoint region. The closest docu-
mented spliced ESTs or mRNA sequences (GenBank ac-
cession numbers AW661872 and BC041841) map ∼96
kb and ∼132 kb to either side of the breakpoint. Further
studies, therefore, focused on the X chromosome, where
an obvious candidate had been identified.
Identification of ZNF41 Mutations in Two Families
with XLMR
Given the absence of this potentially important zinc-
finger protein in the investigated patient with transloca-
tion, we considered ZNF41 to be a candidate disease
gene in families presenting with XLMR. We therefore
screened the ZNF41 coding sequence and neighboring
intronic sequences for disease-causing mutations in 210
unrelated patients with XLMR. We confirmed the pres-
ence of two SNPs (recorded in the GenBank Entrez SNP
database), both present in ∼1.5% of the patients, and
identified four novel nucleotide exchanges (for a com-
plete description of SNPs identified, see table 4). Of par-
ticular interest, we identified one novel amino acid
exchange and one intronic splice-site mutation that were
not found in 1400 control X chromosomes.
In family P13 (with MRX) (depicted in fig. 4A), the
738CrT (GenBank accession number NM_007130) al-
teration results in a proline-to-leucine exchange at amino
acid 111 (P111L [GenBank accession number NP_
009061]) (see fig. 4A). This alteration was absent in the
control individuals screened. The affected amino acid
lies in the linker region between the repressor domain
and the zinc-finger domain. In light of the unique struc-
ture of proline, it is plausible that the tertiary structure
of the protein is modified or destabilized by this ex-
change, which could have significant functional conse-
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Table 4
Summary of Sequence Alterations Identified in Screening ZNF41 DNA in a Panel of Patients with MRX
Exon and
Nucleotide Exchangea Amino Acid Exchangeb
No. of Patients
with Exchange
No. of Control
Chromosomesc Identified Previously
3:
479–42Ar Cd NA 1 0/405 No
5a:
738Cr T P111L 1 0/401 No
780TrG I125R 3 8/401 No
5b:
1192GrA Q262Q 3 NA Yes
5c:
1351TrG D315E 3 NA Yes
5e:
1864ArG Q486Q 1 ND No
NOTE.—Potentially disease-causing mutations are highlighted in boldface italics.
a GenBank accession number NM_007130.
b GenBank accession number NP_009061.
c NA p not applicable; ND p not determined.
d At position 2, with respect to the corresponding exon in variants 41.3 and 41.9.
quences. DNA from nonnuclear family members is not
available for further studies, but sequence analysis of
DNA from the only brother of the patient, who is also
mentally disabled, confirmed the presence of the same
missense mutation. Both affected boys in this family pre-
sented with MRX. The index patient had delayed early
milestones: he was first walking freely at age 17 mo, and,
at age 5 years 8 mo, he was functioning at an intellectual
level of age 3 years (as measured by Brunet-Lezine’s test).
He exhibited language retardation, avoided social con-
tact, and was hyperactive. He had no dysmorphic fea-
tures or additional neurological abnormalities. His older
brother has a similar history. The parents are unrelated,
and both of the mother’s brothers are affected, but ad-
ditional clinical data on other family members are not
available. Analysis of DNA from the mother confirmed
that she carries the same mutation on one of her X
chromosomes (fig. 4A).
In family P42 (with MRX) (fig. 4B), we detected an
adenine-to-cytidine intronic mutation (479-42ArC [Gen-
Bank accession number NM_007130]) (fig. 4B [lower
panel]) that results in aberrant splicing of ZNF41. More
precisely, two documented ZNF41 transcripts—variants
41.3 and 41.6 (corresponding to GenBank accession
numbers AJ010018 and AJ010021, respectively; see also
Rosati et al. [1999])—and one novel ZNF41 transcript,
variant 41.9 described below, contain 5′ extensions of
exon 3 (referred to as “exon 2” by Rosati et al. [1999]
but now updated in NCBI) that make use of the con-
sensus splice site that is mutated in family P42. Our
investigations of the resulting splicing defects in the pa-
tient cell line focused primarily on transcript variant 41.3,
since variant 41.6 is expressed at low levels (see Rosati
et al. [1999]) and could not be readily detected in lym-
phoblastoid cell lines. As depicted in fig. 5A, transcript
variant ZNF41.3 can be amplified in control cell lines
but is absent in the patient cell line. Moreover, exclu-
sively in the patient cell line, larger misspliced transcripts
are present (fig. 5A [top panel]). Analysis of the pre-
dominant transcript variant ZNF41.1 indicated no dif-
ference between patients and control individuals (data not
shown).
It is interesting that we have also identified a novel
splice variant of ZNF41 (designated “41.9” and depicted
in fig. 5B) that lacks exon 2 and therefore, like variant
ZNF41.4 (Rosati et al. 1999), has a predicted ORF that
does not contain the transcriptional repressor domain.
Unlike variant ZNF41.4, however, this variant contains
the 5′ extension of exon 3 that is present in variant
ZNF41.3, and, like variant ZNF41.3, ZNF41.9 is absent
in the patient cell line (fig. 5B). This splice-site mutation
may not directly affect the coding sequence of variant
ZNF41.9, given that the first methionine in the known
mRNA sequence lies in exon 4; however, in variant
ZNF41.3, the intron 2 acceptor splice site follows pre-
dicted amino acid 20, and subsequent skipping of exon
3 would result in the presence of a premature stop codon
in exon 5 (fig. 5A). Like other RNAs with premature
termination codons, such a transcript would likely be
targeted for nonsense-mediated mRNA decay (for review,
see Hentze and Kulozik [1999]). This is supported by
the fact that we did not detect transcripts lacking exon
3 in the patient cell line when using external primers
(data not shown). In any case, it is clear that both
normal variants ZNF41.3 and ZNF41.9 are absent spe-
cifically in the patient, and this probably has functional
consequences.
Like the proline-to-leucine amino acid exchange, this
mutation was not found in other screened patients, nor
was it detected in the control individuals. The patient has
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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucine mutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
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Figure 5 A, RT-PCR for ZNF41.3 in male control (CON 1),
female control (CON 2), and patient (PAT) lymphoblastoid cell lines.
The schematic diagram below the cell lines (not to scale) indicates the
exonic structure of both normal and predicted aberrant ZNF41.3 tran-
scripts, with respect to the predominant transcript variant ZNF41.1,
and the respective locations of primers F2 and R1 (specific for variants
41.3 and 41.6) used for amplification. Shaded regions indicate pre-
dicted coding sequence; patterns differentiate between reading frames.
The adeninercytidine intronic splice-site mutation in the patient is
underlined and indicated in bold typeface. B, RT-PCR for the novel
transcript variant ZNF41.9 in the same samples. As in section A, the
schematic diagram indicates the intronic mutation, the structure of
ZNF41.9 relative to the predominant transcript ZNF41.1, the location
of primers F1 and R1 used for amplification, and the predicted coding
sequences of the resulting transcript variants. Amplification of HPRT
served as a control. A plus sign () indicates with reverse transcriptase;
a minus sign () indicates mock reaction.
mo, the patient was unable to read, and he had essen-
tially no acquisition of mathematics skills. He had mood
disorders, with both hyperactivity and aggressiveness,
and he required special education. At that time, his ver-
bal IQ score was 83, and performance IQ was 59 (as
measured by Wechsler’s scale). Cerebral MRI results
were normal. The younger sister of this patient recently
received a diagnosis of a borderline form of MR. She
also had school difficulties associated with impulsive be-
havior and hyperactivity. Sequencing confirmed that she
is heterozygous for the splice-site mutation (see fig. 4B).
The father does not carry the mutation; it was inherited
from the mother, who is also a carrier (fig. 4B). We have
no clinical data suggesting that the mother is affected,
but we never directly addressed that question.
ZNF41 Is Expressed in Multiple Tissues, Including Fetal
and Adult Brain
Little is known about the physiological role of the
ZNF41 gene; we therefore investigated its expression
pattern in both adult and fetal tissues. A predominant
transcript was observed at ∼3 kb. The transcript is pre-
sent in all adult tissues tested, with relatively low ex-
pression in lung and liver (fig. 6A). ZNF41 is also tran-
scribed in all fetal tissues tested and shows a similar
pattern (fig. 6B). High-stringency hybridization of the
ZNF41 cDNA to an adult multiple-brain tissue northern
blot also confirmed ubiquitous expression (fig. 6C). It is
interesting that a larger transcript of ∼6 kb was detected
at significant levels, specifically in fetal brain. The pres-
ence of a transcript of the same size was also observed
at very low levels in adult skeletal muscle; however, ow-
ing to the high levels of RNA present in this sample, no
conclusions can be drawn about the tissue specificity of
this transcript in the adult. There is currently no data
in GenBank to suggest that this band represents cross-
hybridization with a closely related gene. Another tran-
script of ∼2 kb in length was observed exclusively in
adult heart. Expression of both the expected 3-kb tran-
scripts and the uncharacterized 6-kb transcript in fetal
brain supports a role for the ZNF41 gene in early cog-
nitive development.
Discussion
We have shown that the KRAB/FPB gene-family member
ZNF41 is disrupted in a female patient with severe MR
who carries a de novo reciprocal translocation t(X;7)
(p11.3;q11.21). ZNF41 is subject to X inactivation (Ro-
sati et al. 1999); therefore, preferential inactivation of
the normal X chromosome results in absence of ZNF41
transcripts in the patient, which strongly suggests that
loss of functional ZNF41 causes the observed mental
disability. The absence of a disrupted gene on chro-
mosome 7 further supports this hypothesis. In addition,
we identified two potentially disease-causing ZNF41 se-
quence alterations in unrelated families with XLMR.
One of these mutations results in aberrant splicing of
two ZNF41 isoforms; the other results in exchange of
a proline for a leucine residue, which may affect the
protein structure. Together, these results strongly suggest
that functional alterations in ZNF41 affect cognitive
development.
Krueppel-type zinc-finger genes are evolutionarily con-
served transcriptional regulators characterized by their
Cys2 His2 zinc binding motif, which is typically respon-
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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney. C, Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conserved N-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulation may play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by which MECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
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finger of KAP-1 is required for KRAB/ZFP-associated
transcriptional repression, the association between the
PHD-containing ATRX and MR is especially interesting.
ATRX mutations, like KAP-1 mutations, probably in-
hibit the PHD-dependent formation of multiprotein com-
plexes required for chromatin remodeling. It is there-
fore conceivable that ATRX mutations and loss of
KRAB/ZFP/KAP-1 function lead to MR via similar de-
fects in regulation of chromatin structure.
It may be of significance that many human genes be-
longing to the KRAB/ZFP family have no obvious or-
thologue in the mouse. In a recent study on a conserved
cluster of these genes on chromosome 19, it was ascer-
tained that, for 21 functional human KRAB/ZFPs, there
are only 10 corresponding mouse genes. Shannon et al.
(2003) suggest that duplication events occurring after
human-rodent evolutionary divergence are responsible
for this phenomenon, and they put forward the hy-
pothesis that sequence and functional variations in these
duplicated proteins play a role in establishing species-
specific traits (Shannon et al. 2003). In light of this, it
is interesting that in silico analysis of both publicly
available EST sequences and alignment of fully an-
notated human and mouse genomic sequence (Genome
Browser [April 2003 freeze and February 2003 freeze,
respectively]) suggest that ZNF41 is one of the KRAB
zinc-finger genes for which there is no mouse ortho-
logue. It is enticing to propose that this subset of KRAB/
ZFPs may be specifically important for some of the psy-
chological and cognitive traits that distinguish humans
from lower mammals.
KRAB zinc-finger proteins are indeed involved in vari-
ous aspects of physical and intellectual human develop-
ment and are therefore excellent candidate genes for MR.
Since several other potential causes have been ruled out,
it is very likely that loss of functional ZNF41 causes
the MR observed in our patient with translocation. The
identification of two potentially disease-causing ZNF41
mutations in unrelated families with MRX further sup-
ports a role for this transcription factor in cognition. The
presence of a leucine instead of a proline at ZNF41.1
amino acid position 111 (P111L) may cause structural
changes that interfere with normal function of the pro-
tein. Perhaps of even greater significance is the mutation
found in a second family that disrupts normal splicing
of ZNF41. We have shown that two specific ZNF41
transcript variants that make use of the relevant splice
site are absent in the patient cell line, suggesting that
loss of function of these variants causes the phenotype
in the index patient and in his mildly affected sister. It
is noteworthy that there are several documented ex-
amples of X-linked cognitive disorders that exhibit wide
intrafamilial phenotypic variability, sometimes present-
ing as behavior disorders or mild cognitive impairment
in carrier females. In particular, this applies in the case
of the L1CAM mutation in a large family described by
Ruiz et al. (1995) in which some carrier females partially
express the phenotype although others are normal. Simi-
larly, RSK2 mutations, implicated in Coffin-Lowry syn-
drome (MIM 303600), are associated with a range of
mild cognitive deficits in carrier females (Simensen et
al. 2002). Also, mutations in the creatine-transporter
gene SLC6A8 (MIM 300036), recently implicated in
MR, result in various learning disabilities and behavior
problems in heterozygous females (Salomons et al.
2001; Hahn et al. 2002). It is interesting that, like the
ZNF41 mutation we identified in family P42, one of
these familial SLC6A8 mutations is also associated with
aberrant splicing (Hahn et al. 2002). It is clear that
aberrant splicing can have a range of consequences for
cognitive function. Indeed, such mutations in several
genes—including both L1CAM and RSK2 (Finckh et al.
2000; Delaunoy et al. 2001) and ATRX (Villard et al.
1996b; Fichera et al. 2001)—have highlighted the link
between splicing defects and various forms of MR.
It is also important to recognize that the frequency
of causative mutations in any single MRX gene iden-
tified to date is relatively low. For example, a mutation
in ARHGEF6 (MIM 300267), one of the 13 known
genes implicated in monogenic forms of MR, was found
in only 1 of 119 families with MRX screened (Kutsche
et al. 2000). Alterations in ZNF41 are associated with
MR in 2 of 210 unrelated patients screened, and, in
addition, our patient with translocation has no func-
tional ZNF41. We conclude that ZNF41 is a good can-
didate gene for MRX. Further studies will shed more
light on the mechanisms by which mutations in the
ZNF41 gene result in dysfunction of the brain.
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